Literature DB >> 28701393

HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Vijaya Madhavi1, Bruce D Wines2,3,4, Janaki Amin5, Sean Emery5, Ester Lopez1, Anthony Kelleher5,6, Rob J Center1,2, P Mark Hogarth2, Amy W Chung1, Stephen J Kent7,8,9, Ivan Stratov1,8.   

Abstract

Studying HIV-infected individuals who control HIV replication (elite controllers [ECs]) enables exploration of effective anti-HIV immunity. HIV Env-specific and non-Env-specific antibody-dependent cellular cytotoxicity (ADCC) may contribute to protection from progressive HIV infection, but the evidence is limited. We recruited 22 ECs and matched them with 44 viremic subjects. HIV Env- and Vpu-specific ADCC responses in sera were studied using a novel enzyme-linked immunosorbent assay (ELISA)-based dimeric recombinant soluble FcγRIIIa (rsFcγRIIIa)-binding assay, surface plasmon resonance, antibody-dependent natural killer (NK) cell activation assays, and ADCC-mediated killing assays. ECs had higher levels of HIV Env-specific antibodies capable of binding FcγRIIIa, activating NK cells, and mediating granzyme B activity (all P < 0.01) than viremic subjects. ECs also had higher levels of antibodies against a C-terminal 13-mer Vpu peptide capable of mediating FcγRIIIa binding and NK cell activation than viremic subjects (both P < 0.05). Our data associate Env-specific and Vpu epitope-specific ADCC in effective immune responses against HIV among ECs. Our findings have implications for understanding the role of ADCC in HIV control.IMPORTANCE Understanding immune responses associated with elite control of HIV may aid the development of immunotherapeutic and vaccine strategies for controlling HIV infection. Env is a major HIV protein target of functional antibody responses that are heightened in ECs. Interestingly, EC antibodies also target Vpu, an accessory protein crucial to HIV, which degrades CD4 and antagonizes tetherin. Antibodies specific to Vpu are a common feature of the immune response of ECs that may prove to be of functional importance to the design of improved ADCC-based immunotherapy and preventative HIV vaccines.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ADCC; FcγR; Vpu; elite controller

Mesh:

Substances:

Year:  2017        PMID: 28701393      PMCID: PMC5571238          DOI: 10.1128/JVI.00700-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Authors:  Camille Lécuroux; Asier Sáez-Cirión; Isabelle Girault; Pierre Versmisse; Faroudy Boufassa; Véronique Avettand-Fenoël; Christine Rouzioux; Laurence Meyer; Gianfranco Pancino; Olivier Lambotte; Martine Sinet; Alain Venet
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

2.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.

Authors:  Nia D Banks; Nicole Kinsey; Janice Clements; James E K Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

4.  The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release.

Authors:  Jason Hammonds; Lingmei Ding; Hin Chu; Ken Geller; Andrew Robbins; Jaang-Jiun Wang; Hong Yi; Paul Spearman
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.

Authors:  Rob J Center; Adam K Wheatley; Shahan M Campbell; Adriana J Gaeguta; Viv Peut; Sheilajen Alcantara; Carly Siebentritt; Stephen J Kent; Damian F J Purcell
Journal:  Vaccine       Date:  2009-08-25       Impact factor: 3.641

7.  Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

Authors:  Vijaya Madhavi; Fernanda E Ana-Sosa-Batiz; Sinthujan Jegaskanda; Rob J Center; Wendy R Winnall; Matthew S Parsons; Jintanat Ananworanich; David A Cooper; Anthony D Kelleher; Denise Hsu; Sarah Pett; Ivan Stratov; Marit Kramski; Stephen J Kent
Journal:  J Infect Dis       Date:  2014-08-28       Impact factor: 5.226

Review 8.  [Elite controllers and the mechanisms behind spontaneous control of HIV].

Authors:  David Shasha
Journal:  Harefuah       Date:  2013-08

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

10.  Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease.

Authors:  John Zaunders; David van Bockel
Journal:  Front Immunol       Date:  2013-04-24       Impact factor: 7.561

View more
  36 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

Review 2.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 3.  Engaging innate immunity in HIV-1 cure strategies.

Authors:  Nathan L Board; Milica Moskovljevic; Fengting Wu; Robert F Siliciano; Janet D Siliciano
Journal:  Nat Rev Immunol       Date:  2021-11-25       Impact factor: 108.555

Review 4.  Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.

Authors:  Evan Rossignol; Galit Alter; Boris Julg
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

5.  Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells.

Authors:  Evan D Rossignol; Anne-Sophie Dugast; Hacheming Compere; Christopher A Cottrell; Jeffrey Copps; Shu Lin; Deniz Cizmeci; Michael S Seaman; Margaret E Ackerman; Andrew B Ward; Galit Alter; Boris Julg
Journal:  Cell Rep       Date:  2021-05-25       Impact factor: 9.423

6.  Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.

Authors:  Franck P Dupuy; Nicole F Bernard; Lauren Nagel; Sanket Kant; Christopher Leeks; Jean-Pierre Routy; Cécile Tremblay; Réjean Thomas; Jason Szabo; Pierre Côté; Benoit Trottier; Roger LeBlanc; Danielle Rouleau
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

7.  A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.

Authors:  Allison S Thomas; Melissa Ghulam-Smith; Alex Olson; Carolyn Coote; Oscar Gonzales; Manish Sagar
Journal:  J Immunol Methods       Date:  2020-03-02       Impact factor: 2.287

Review 8.  Prospects from systems serology research.

Authors:  Kelly B Arnold; Amy W Chung
Journal:  Immunology       Date:  2017-12-01       Impact factor: 7.397

9.  Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates.

Authors:  María Julia Ruiz; Jimena Salido; Lorena Abusamra; Yanina Ghiglione; Cintia Cevallos; Gabriel Damilano; Ana María Rodriguez; César Trifone; Natalia Laufer; Luis D Giavedoni; Omar Sued; Horacio Salomón; María Magdalena Gherardi; Gabriela Turk
Journal:  EBioMedicine       Date:  2017-11-03       Impact factor: 8.143

Review 10.  Vaccinating for natural killer cell effector functions.

Authors:  Helen R Wagstaffe; Jason P Mooney; Eleanor M Riley; Martin R Goodier
Journal:  Clin Transl Immunology       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.